176 related articles for article (PubMed ID: 36216618)
1. Impact of margin accentuation with intraoperative irreversible electroporation on local recurrence in resected pancreatic cancer.
Martin RCG; Schoen EC; Philips P; Egger ME; McMasters KM; Scoggins CR
Surgery; 2023 Mar; 173(3):581-589. PubMed ID: 36216618
[TBL] [Abstract][Full Text] [Related]
2. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
Kwon D; McFarland K; Velanovich V; Martin RC
Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
[TBL] [Abstract][Full Text] [Related]
3. Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation - Results from the MACPIE-I study.
Kundalia K; Hakeem A; Papoulas M; Mcphail M; Reddy S; Peddu P; Kibriya N; Atkinson S; Prachalias A; Srinivasan P; Heaton N; Sarker D; Ross P; Zen Y; Menon K
Eur J Surg Oncol; 2021 Oct; 47(10):2571-2578. PubMed ID: 34039473
[TBL] [Abstract][Full Text] [Related]
4. Irreversible electroporation as treatment of locally advanced and as margin accentuation in borderline resectable pancreatic adenocarcinoma.
Marsanic P; Mellano A; Sottile A; De Simone M
Med Biol Eng Comput; 2017 Jul; 55(7):1123-1127. PubMed ID: 28078482
[TBL] [Abstract][Full Text] [Related]
5. Margin Accentuation Irreversible Electroporation in Stage III Pancreatic Cancer: A Systematic Review.
Ratnayake B; Al-Leswas D; Mohammadi-Zaniani G; Littler P; Sen G; Manas D; Pandanaboyana S
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34199031
[TBL] [Abstract][Full Text] [Related]
6. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival.
Martin RC; McFarland K; Ellis S; Velanovich V
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S443-9. PubMed ID: 23128941
[TBL] [Abstract][Full Text] [Related]
7. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of local recurrence after pancreaticoduodenectomy for borderline resectable pancreatic head cancer with neoadjuvant chemotherapy: Can the resection level change after chemotherapy?
Kobayashi K; Ono Y; Sato S; Kato T; Oba A; Sato T; Ito H; Inoue Y; Takamatsu M; Saiura A; Takahashi Y
Surgery; 2023 May; 173(5):1220-1228. PubMed ID: 36424197
[TBL] [Abstract][Full Text] [Related]
9. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.
Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J
Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234
[TBL] [Abstract][Full Text] [Related]
10. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma.
Martin RC; McFarland K; Ellis S; Velanovich V
J Am Coll Surg; 2012 Sep; 215(3):361-9. PubMed ID: 22726894
[TBL] [Abstract][Full Text] [Related]
11. Multi-institutional review of adverse events associated with irreversible electroporation in the treatment of locally advanced pancreatic cancer.
Stephens K; Philips PP; Egger ME; Scoggins CR; McMasters KM; Martin RCG
Surgery; 2024 Mar; 175(3):704-711. PubMed ID: 37852831
[TBL] [Abstract][Full Text] [Related]
12. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer.
Kang CM; Chung YE; Park JY; Sung JS; Hwang HK; Choi HJ; Kim H; Song SY; Lee WJ
J Gastrointest Surg; 2012 Mar; 16(3):509-17. PubMed ID: 22183861
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer.
McClaine RJ; Lowy AM; Sussman JJ; Schmulewitz N; Grisell DL; Ahmad SA
HPB (Oxford); 2010 Feb; 12(1):73-9. PubMed ID: 20495649
[TBL] [Abstract][Full Text] [Related]
14. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
Barnes CA; Aldakkak M; Christians KK; Clarke CN; Dua K; George B; Ritch PS; Kamgar M; Hall WA; Kulkarni N; Erickson BA; Evans DB; Tsai S
Surgery; 2020 Sep; 168(3):440-447. PubMed ID: 32641278
[TBL] [Abstract][Full Text] [Related]
15. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas.
Dunki-Jacobs EM; Philips P; Martin RC
J Am Coll Surg; 2014 Feb; 218(2):179-87. PubMed ID: 24315888
[TBL] [Abstract][Full Text] [Related]
17. The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy.
Ansari D; Kristoffersson S; Andersson R; Bergenfeldt M
Scand J Gastroenterol; 2017 Nov; 52(11):1165-1171. PubMed ID: 28687047
[TBL] [Abstract][Full Text] [Related]
18. Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients.
Kluger MD; Epelboym I; Schrope BA; Mahendraraj K; Hecht EM; Susman J; Weintraub JL; Chabot JA
Ann Surg Oncol; 2016 May; 23(5):1736-43. PubMed ID: 26714959
[TBL] [Abstract][Full Text] [Related]
19. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
Rashid OM; Pimiento JM; Gamenthaler AW; Nguyen P; Ha TT; Hutchinson T; Springett G; Hoffe S; Shridhar R; Hodul PJ; Johnson BL; Illig K; Armstrong PA; Centeno BA; Fulp WJ; Chen DT; Malafa MP
Ann Surg Oncol; 2016 Apr; 23(4):1371-9. PubMed ID: 26661409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
